Showing results (161-170 of 223) with videos related to
Sort By:
Pageof 23
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 21, 2023
Performance of McDonald 2017 multiple sclerosis diagnostic criteria and evaluation of genetic ancestry in patients with a first demyelinating event in ArgentinaMariano Marrodan, Maria Agustina Piedrabuena, Maria Ines Gaitan, et al.Multiple Sclerosis and Related Disorders|July 3, 2023
Latin American consensus recommendations on the risk of infections in people with multiple sclerosis treated with disease modifying drugsBerenice A Silva, Edgar Carnero Contentti, Jefferson Becker, et al.ASN Neuro|April 24, 2023
Transferrin Enhances Neuronal DifferentiationMaría Julia Pérez, Tomas Roberto Carden, Paula Ayelen Dos Santos Claro, et al.Therapeutic Advances in Neurological Disorders|December 14, 2011
Optimizing outcomes in multiple sclerosis: consensus guidelines for the diagnosis and treatment of multiple sclerosis in Latin AmericaAdriana Carrá, Miguel Ángel Macías-Islas, Alberto Alan Gabbai, et al.The Lancet. Neurology|November 21, 2022
Multiple sclerosis progression: time for a new mechanism-driven frameworkTanja Kuhlmann, Marcello Moccia, Timothy Coetzee, et al.Applied Neuropsychology. Adult|November 22, 2021
Theory of mind, emotion recognition and emotional reactivity factors in early multiple sclerosis: Results from a South American cohortLucia Crivelli, Ismael Luis Calandri, Belén Helou, et al.Journal of Clinical Immunology|September 17, 2009
Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cellsYaron Ilan, Ehud Zigmond, Gadi Lalazar, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|April 4, 2023
Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective studyGavin Giovannoni, Alexey Boyko, Jorge Correale, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|December 18, 2024
Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohortGavin Giovannoni, Alexey Boyko, Jorge Correale, et al.Neurodegenerative Disease Management|August 3, 2023
A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS studyGavin Giovannoni, Alexey Boyko, Jorge Correale, et al.Pageof 23